ANTI-OBESITY TREATMENT COULD COST AS LITTLE AS $3 PER MONTH – STUDY
Fri 06 March 2026: A blockbuster anti-obesity and diabetes drug could cost as little as $3 per month to manufacture once it goes off patent later this month, researchers said Friday, providing a major opportunity to boost health in low and middle-income countries. Semaglutide, the active molecule in Novo Nordisk’s Ozempic and Wegovy treatments, leads […]
Continue Reading
